UPCC 50420 Immunologic Assessment of Hodgkin Lymphoma Patients Treated with Itacitinib in Combination with Everolimus

Enrolling By Invitation
99 years or below
All
Phase N/A
23 participants needed
1 Location

Brief description of study

To investigate immunologic changes in Hodgkin Lymphoma patients treated with itacitinib (a JAK inhibitor) in combination with everolimus (an mTOR inhibitor).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 20-1404
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator